Bismarck News Updates

New Therapeutics Options for Tendinitis Treatment as 4+ Companies are working for the Drug Profiles

 Breaking News
  • No posts were found

New Therapeutics Options for Tendinitis Treatment as 4+ Companies are working for the Drug Profiles

May 25
15:48 2021
New Therapeutics Options for Tendinitis Treatment as 4+ Companies are working for the Drug Profiles

Tendinitis Pipeline
The Tendinitis Pipeline Insights Report from DelveInsight offers detailed insights into the Tendinitis pipeline environment, including 4+ companies and 4+ pipeline products. It includes clinical and nonclinical stage products in the pipeline drug profiles. It also examines therapeutics by product form, level, administration path, and molecule type.

The Tendinitis Pipeline Insights Report from DelveInsight offers detailed insights into the Tendinitis pipeline environment, including 4+ companies and 4+ pipeline products. It includes clinical and nonclinical stage products in the pipeline drug profiles. It also examines therapeutics by product form, level, administration path, and molecule type.

Some Crucial Highlights from the Tendinitis Pipeline Report

  • There are currently 4+ Tendinitis pipeline therapies in different stages of development, and their anticipated introduction into the Tendinitis market will result in significant market revenue growth.

  • Pipeline therapies include dHACM is in Phase III clinical trials for Tendinitis, whereas Amniotic Fluid is in the Phase II/III clinical trials.

  • Some emerging therapies for Tendinitis, such as SI-613 and Autologous Pure Platelet-rich Plasma are in the Phase II of clinical development.

  • Tendinitis pipeline therapies in the early stage of development include CWT 001 in the Phase I of clinical trials.

  • Among the companies developing new drug candidates to boost the Tendinitis pipeline landscape are MiMedx, R3 Stem Cell, Seikagaku Corporation, Zhejiang Xingyue Biotechnology, Causeway Therapeutics and others.

To get more information request sample @ Tendinitis Pipeline Insights Landscape

Tendinitis: Disease Overview

Tendinitis is an inflammation or irritation of a tendon, which is a thick cord that connects bone to muscle. Tendinitis can strike almost anywhere a tendon attaches a bone to a muscle on the body. The base of the thumb, elbow, shoulder, hip, knee, and achilles tendon are the most common locations.

Tendinitis: Symptoms

Symptoms of Tendinitis are:

  • Tendinitis causes pain at the tendon’s location as well as the surrounding region. Pain may come on gradually or suddenly, particularly if calcium deposits are present.

  • Shoulder stiffness, also known as “adhesive capsulitis” or “frozen shoulder.”

Tendinitis: Treatment

The treatment’s aims are to get the joint moving again without causing discomfort and to keep the underlying muscles strong as the tissues recover. Doctors and physical therapists also prescribe the RICE programme as an immediate cure for Tendinitis: Rest, Ice, Compression, and Elevation of the injured tendon.

For more insights visit Tendinitis Causes, Diagnosis and Treatment

Tendinitis Pipeline Analysis: Drug Profile

dHACM: MiMedx

Product Description

MiMedx is developing dHACM, a micronized dehydrated Human Amnion Chorion Membrane, for Tendinitis. It is currently in phase III of development. Purion, a proprietary system for placental-based allografts that meets the American Association of Tissue Banks (AATB) guidelines, is used to process AmnioFix.

Research and Development in the Tendinitis Pipeline Landscape

Phase III

NCT03414255: MiMedx began a “Phase 3 Prospective, Double-Blind, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection in the Treatment of Achilles Tendonitis” in January of 2018. Micronized dHACM Injection vs. Saline Placebo Injection in the Treatment of Achilles Tendonitis: A Prospective, Double-Blind, Randomized Controlled Trial

Tendinitis Pipeline Therapies and Key Companies

  • dHACM: MiMedx

  • Amniotic Fluid : R3 Stem Cell

  • SI-613: Seikagaku Corporation

  • Autologous Pure Platelet-rich Plasma: Zhejiang Xingyue Biotechnology

  • CWT 001: Causeway Therapeutics

Tendinitis Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Tendinitis Key Players: MiMedx, R3 Stem Cell, Seikagaku Corporation, Zhejiang Xingyue Biotechnology, Causeway Therapeutics, among others

Tendinitis Pipeline Therapies: dHACM, Amniotic Fluid, SI-613, Autologous Pure Platelet-rich Plasma, CWT 001, others

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Tendinitis: Overview

4.

Tendinitis- Analytical Perspective In-depth Commercial Assessment

5.

Tendinitis: Pipeline Therapeutics

6.

Tendinitis Late Stage Products (Phase III)

7.

Tendinitis Mid Stage Products (Phase II/III)

8.

Tendinitis Mid Stage Products (Phase II)

9.

Tendinitis Early Stage Products (Phase I)

10.

Tendinitis Therapeutic Assessment

11.

Tendinitis Inactive Products

12.

Tendinitis Company-University Collaborations (Licensing/Partnering) Analysis

13.

Tendinitis Key Companies

14.

Tendinitis Key Products

15.

Tendinitis- Unmet Needs

16.

Tendinitis- Market Drivers and Barriers

17.

Tendinitis- Future Perspectives and Conclusion

18.

Tendinitis Analyst Views

19.

Appendix

20.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key Questions Answered in the Tendinitis Pipeline Report

  • What are the treatment choices for Tendinitis?

  • How many companies are developing Tendinitis treatments?

  • What are the most popular treatments produced by these companies?

  • How many Tendinitis therapies has each company produced in total?

  • In the early, middle, and late stages of Tendinitis, how many new therapies are being developed?

  • How many of the drugs in the pipeline can be used alone or in combination with other treatments?

  • What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises that will impact Tendinitis?

Related Reports

Atypical Teratoid Rhabdoid Tumors Pipeline Insights

Get comprehensive analysis of Atypical Teratoid Rhabdoid Tumors  pipeline therapies and key companies including Takeda Oncology, Epizyme, Vyriad Inc., DNAtrix, Pfizer, Oncoceutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Categories